These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae. Rice CA; Colon BL; Chen E; Hull MV; Kyle DE PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008353. PubMed ID: 32970675 [TBL] [Abstract][Full Text] [Related]
8. Natural Terpenes Inhibit the Cytopathogenicity of Rajendran K; Ahmed U; Meunier AC; Shaikh MF; Siddiqui R; Anwar A ACS Chem Neurosci; 2023 Dec; 14(23):4105-4114. PubMed ID: 37983556 [No Abstract] [Full Text] [Related]
9. Repositioning of Guanabenz in Conjugation with Gold and Silver Nanoparticles against Pathogenic Amoebae Anwar A; Mungroo MR; Anwar A; Sullivan WJ; Khan NA; Siddiqui R ACS Infect Dis; 2019 Dec; 5(12):2039-2046. PubMed ID: 31612700 [TBL] [Abstract][Full Text] [Related]
10. Amoebicidal effect of chlorine dioxide gas against pathogenic Naegleria fowleri and Acanthamoeba polyphaga. Sohn HJ; Park AY; Lee JH; Yun KH; Song KJ; Kim JH; Shin HJ Parasitol Res; 2024 Apr; 123(4):192. PubMed ID: 38652173 [TBL] [Abstract][Full Text] [Related]
11. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). Debnath A; Calvet CM; Jennings G; Zhou W; Aksenov A; Luth MR; Abagyan R; Nes WD; McKerrow JH; Podust LM PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006104. PubMed ID: 29284029 [TBL] [Abstract][Full Text] [Related]
12. Azole and 5-nitroimidazole based nanoformulations are potential antiamoebic drug candidates against brain-eating amoebae. Akbar N; Hussain K; Khalid M; Siddiqui R; Shah MR; Khan NA J Appl Microbiol; 2023 Apr; 134(4):. PubMed ID: 37024269 [TBL] [Abstract][Full Text] [Related]
13. Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri. Kim JH; Jung SY; Lee YJ; Song KJ; Kwon D; Kim K; Park S; Im KI; Shin HJ Antimicrob Agents Chemother; 2008 Nov; 52(11):4010-6. PubMed ID: 18765686 [TBL] [Abstract][Full Text] [Related]
14. Differential Growth Rates and Russell AC; Kyle DE Microbiol Spectr; 2022 Feb; 10(1):e0189921. PubMed ID: 35138140 [TBL] [Abstract][Full Text] [Related]
15. Relaxed Substrate Requirements of Sterol 14α-Demethylase from Hargrove TY; Wawrzak Z; Rachakonda G; Nes WD; Villalta F; Guengerich FP; Lepesheva GI J Med Chem; 2021 Dec; 64(23):17511-17522. PubMed ID: 34842434 [No Abstract] [Full Text] [Related]
17. Therapeutic effect of rokitamycin in vitro and on experimental meningoencephalitis due to Naegleria fowleri. Kim JH; Lee YJ; Sohn HJ; Song KJ; Kwon D; Kwon MH; Im KI; Shin HJ Int J Antimicrob Agents; 2008 Nov; 32(5):411-7. PubMed ID: 18762406 [TBL] [Abstract][Full Text] [Related]
18. Anti-Balamuthia mandrillaris and anti-Naegleria fowleri effects of drugs conjugated with various nanostructures. Siddiqui R; Boghossian A; Alqassim SS; Kawish M; Gul J; Jabri T; Shah MR; Khan NA Arch Microbiol; 2023 Apr; 205(5):170. PubMed ID: 37017767 [TBL] [Abstract][Full Text] [Related]
19. Identification of cysteine protease inhibitors as new drug leads against Naegleria fowleri. Zyserman I; Mondal D; Sarabia F; McKerrow JH; Roush WR; Debnath A Exp Parasitol; 2018 May; 188():36-41. PubMed ID: 29551628 [TBL] [Abstract][Full Text] [Related]
20. Repurposing in vitro approaches for screening anti-parasitic drugs against the brain-eating amoeba Naegleria fowleri. Martín-Escolano R; Yiangou L; Kazana E; Robinson GK; Michaelis M; Tsaousis AD Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():204-212. PubMed ID: 34875573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]